Demographical features of the sample. حسب Aymee Lobato Brito (19812790)

"…Individuals with the multibacillary type exhibit a propensity for developing chronic pain and a decrease in sensitivity in the plantar region, which directly interferes with balance maintenance. …"

Correlation description. حسب Aymee Lobato Brito (19812790)

"…Individuals with the multibacillary type exhibit a propensity for developing chronic pain and a decrease in sensitivity in the plantar region, which directly interferes with balance maintenance. …"

<i>NDUFS7</i> depletion in motor neurons affects synapse stability. حسب Bhagaban Mallik (12459375)

"…The motor neuron-depleted <i>NDUFS7[RNAi]</i> larvae showed a decrease in the number of Futsch-positive loops as compared to the Gal4 control. …"

Western blot antibody information. حسب Shuailin Li (11907158)

"…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…"

Information on healthy and aniridia subjects. حسب Shuailin Li (11907158)

"…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…"

qPCR primers information. حسب Shuailin Li (11907158)

"…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…"

Data Sheet 1_Mechanical property changes of glial LC and RGC axons in response to high intraocular pressure.docx حسب Bochao Ma (14572143)

"…Similarly, the Young's modulus of RGC axons decreased by 45.6%, 70.9%, and 75.9% over the same time points. …"

Table 1_Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022–2041.docx حسب Bo Peng (273834)

"…Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022–2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.…"

Supplementary file 1_Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022–2041.doc... حسب Bo Peng (273834)

"…Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022–2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.…"

Presentation 1_Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022–2041.pptx حسب Bo Peng (273834)

"…Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022–2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.…"

Bias risk assessment of included studies. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for hs-CRP. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for IL-6. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Antibodies used for flow cytometry. حسب Shanhe Liu (5251313)

"…</p><p>Results</p><p>Flow cytometry analysis revealed a significantly higher apoptosis rate in AN-LSCs compared to LSCs (p < 0.0001). …"

The incidence rate of adverse reactions. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

The PRISMA study flowchart. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for FEV1/FVC. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Primer pairs used for qPCR. حسب Shanhe Liu (5251313)

"…</p><p>Results</p><p>Flow cytometry analysis revealed a significantly higher apoptosis rate in AN-LSCs compared to LSCs (p < 0.0001). …"

Forest plot for clinical efficacy. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for FEV1. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"